Capricor Therapeutics Inc (OTCMKTS:CAPR) major shareholder Sinai Medical Center Cedars bought 312,500 shares of the firm’s stock in a transaction on Wednesday, September 21st. The stock was acquired at an average price of $3.20 per share, for a total transaction of $1,000,000.00. Following the transaction, the insider now owns 2,904,798 shares of the company’s stock, valued at $9,295,353.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Capricor Therapeutics Inc (OTCMKTS:CAPR) opened at 3.29 on Tuesday. The company has a 50 day moving average price of $3.67 and a 200-day moving average price of $3.55. The firm’s market capitalization is $59.07 million. Capricor Therapeutics Inc has a 1-year low of $1.88 and a 1-year high of $5.40.
Capricor Therapeutics (OTCMKTS:CAPR) last announced its earnings results on Monday, August 15th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.02. On average, analysts forecast that Capricor Therapeutics Inc will post ($1.04) EPS for the current fiscal year.
A number of analysts have recently commented on CAPR shares. Roth Capital started coverage on Capricor Therapeutics in a research note on Wednesday, June 15th. They set a “buy” rating and a $12.00 price target on the stock. HC Wainwright assumed coverage on Capricor Therapeutics in a research note on Wednesday, July 6th. They set a “buy” rating and a $13.00 price target on the stock. Finally, Zacks Investment Research lowered Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 18th.
A hedge fund recently raised its stake in Capricor Therapeutics stock. Sabby Management LLC raised its position in Capricor Therapeutics Inc (OTCMKTS:CAPR) by 8.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 202,083 shares of the company’s stock after buying an additional 16,419 shares during the period. Sabby Management LLC owned approximately 1.24% of Capricor Therapeutics worth $513,000 as of its most recent filing with the SEC.
About Capricor Therapeutics
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.
Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.